Affordable Access

deepdyve-link
Publisher Website

Acetylcholinesterase Inhibitors Are Associated with Reduced Fracture Risk among Older Veterans with Dementia.

Authors
  • Ogunwale, Abayomi N1, 2
  • Colon-Emeric, Cathleen S1, 2
  • Sloane, Richard1, 2
  • Adler, Robert A3, 4
  • Lyles, Kenneth W1, 2
  • Lee, Richard H1, 2
  • 1 Department of Medicine, Duke University, Durham, NC, USA.
  • 2 Durham Veterans Affairs Medical Center, Durham, NC, USA.
  • 3 Hunter Holmes McGuire Veterans Affairs Medical Center, Richmond, VA, USA.
  • 4 Virginia Commonwealth University School of Medicine, Richmond, VA, USA.
Type
Published Article
Journal
Journal of Bone and Mineral Research
Publisher
Wiley (John Wiley & Sons)
Publication Date
Mar 01, 2020
Volume
35
Issue
3
Pages
440–445
Identifiers
DOI: 10.1002/jbmr.3916
PMID: 31711264
Source
Medline
Keywords
Language
English
License
Unknown

Abstract

Acetylcholinesterase inhibitors (AChEIs) have been noted to increase bone density and quality in mice. Human studies are limited but suggest an association with improved bone healing after hip fracture. We examined the relationship between AChEI use and fracture risk in a national cohort of 360,015 male veterans aged 65 to 99 years with dementia but without prior fracture using Veterans Affairs (VA) hospital, Medicare, and pharmacy records from 2000 to 2010. Diagnosis of dementia, any clinical fracture (excluding facial and digital), comorbidities, and medications were identified using ICD-9 and drug class codes. Cox proportional hazard models considering AChEI use as a time-varying covariate and adjusting for fall and fracture risk factors compared the time-to-fracture in AChEI users versus non-AChEI users. Potential confounders included demographics (age, race, body mass index), comorbidities associated with fracture or falls (diabetes, lung disease, stroke, Parkinson's, seizures, etc.) and medications associated with fracture or falls (bisphosphonates, glucocorticoids, androgen deprivation therapy [ADT], proton pump inhibitors [PPIs], selective serotonin receptor inhibitors [SSRIs], etc.). Competing mortality risk was considered using the methods of Fine and Gray. To account for persistent effects on bone density or quality that might confer protection after stopping the medication, we completed a secondary analysis using the medication possession ratio (MPR) as a continuous variable in logistic regression models and also compared MPR increments of 10% to minimal/no use (MPR 0 to <0.10). Among older veterans with diagnosis of dementia, 20.1% suffered a fracture over an average of 4.6 years of follow-up. Overall, 42.3% of the cohort were prescribed AChEIs during the study period. The hazard of any fracture among AChEI users compared with those on other/no dementia medications was significantly lower in fully adjusted models (hazard ratio [HR] = 0.81; 95% confidence interval [CI] 0.75-0.88). After considering competing mortality risk, fracture risk remained 18% lower in veterans using AChEIs (HR = 0.82; 95% CI 0.76-0.89). © 2019 American Society for Bone and Mineral Research. Published 2019. This article is a U.S. Government work and is in the public domain in the USA. Published 2019. This article is a U.S. Government work and is in the public domain in the USA.

Report this publication

Statistics

Seen <100 times